CD4 and neoplasm: FAP-IL2v treatment did not alter the number of CD4+ T cells in tumors compared with the vehicle-treated group, but there was higher increase of CD4+ T cells in the tumor on day 7 compared to Day 5, which is consistent with the findings of the tracer (Supplementary Figure 4).